Risk of Moderate to Advanced Kidney Disease in Patients with Psoriasis: Population Based Cohort Study

Overview

Journal BMJ

Specialty General Medicine

Date 2013 Oct 17

PMID 24129480

Citations 82

Authors

Joy Wan

Shuwei Wang

Kevin Haynes

Michelle R Denburg

Daniel B Shin

Joel M Gelfand

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the risk of chronic kidney disease in patients with psoriasis.

Design: Population based cohort study and nested cross sectional study.

Setting: Electronic medical records database based in United Kingdom.

Participants: Cohort study: patients with psoriasis aged 18-90 each matched to up to five patients without psoriasis based on age, practice, and time of visit. Nested study: patients with psoriasis aged 25-64 with confirmed data on psoriasis severity, each matched to up to 10 patients without psoriasis based on age and practice.

Main Outcome Measures: Cohort study: incident moderate to advanced (stage 3 through 5) chronic kidney disease. Nested study: baseline prevalence of chronic kidney disease.

Results: 136,529 patients with mild psoriasis and 7354 patients with severe psoriasis based on treatment patterns were matched to 689,702 unaffected patients. The adjusted hazard ratios (95% confidence intervals) for incident chronic kidney disease were 1.05 (1.02 to 1.07), 0.99 (0.97 to 1.02), and 1.93 (1.79 to 2.08) in the overall, mild, and severe psoriasis groups, respectively. Age was a significant effect modifier in the severe psoriasis group, with age specific adjusted hazard ratios (95% confidence intervals) of 3.82 (3.15 to 4.64) and 2.00 (1.86 to 2.17) for patients aged 30 and 60, respectively. In the nested analysis of 8731 patients with psoriasis with measurements of affected body surface area matched to 87,310 patients without psoriasis, the adjusted odds ratios (95% confidence intervals) for chronic kidney disease were 0.89 (0.72 to 1.10), 1.36 (1.06 to 1.74), and 1.58 (1.07 to 2.34) in the mild, moderate, and severe psoriasis groups, respectively.

Conclusions: Moderate to severe psoriasis is associated with an increased risk of chronic kidney disease independent of traditional risk factors.

Citing Articles

Investigation of clinical and subclinical renal damage in Psoriasis.

Kucukyangoz B, Polat M, Kucukyangoz M, Bugdayci G, Metin A Arch Dermatol Res. 2024; 317(1):104.

PMID: 39666126 DOI: 10.1007/s00403-024-03592-y.

Cardiodermatology: the heart of the connection between the skin and cardiovascular disease.

Gelfand J, Song W, Langan S, Garshick M Nat Rev Cardiol. 2024; .

PMID: 39537837 DOI: 10.1038/s41569-024-01097-9.

Chronic kidney disease in patients with psoriatic arthritis: a cohort study.

Kharouf F, Gao S, Al-Matar S, Cook R, Chandran V, Gladman D RMD Open. 2024; 10(4).

PMID: 39510763 PMC: 11552569. DOI: 10.1136/rmdopen-2024-004636.

Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.

Song W, Soffer D, Gelfand J Dermatol Clin. 2024; 42(3):417-428.

PMID: 38796273 PMC: 11128720. DOI: 10.1016/j.det.2024.02.008.

Managing the Patient with Psoriasis and Metabolic Comorbidities.

Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P Am J Clin Dermatol. 2024; 25(4):527-540.

PMID: 38748391 PMC: 11193697. DOI: 10.1007/s40257-024-00857-0.

References

Brauchli Y, Jick S, Miret M, Meier C . Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009; 160(5):1048-56. DOI: 10.1111/j.1365-2133.2008.09020.x. View

Lewis J, Schinnar R, Bilker W, Wang X, Strom B . Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2006; 16(4):393-401. DOI: 10.1002/pds.1335. View

Kaji T, Tsukada Y, Shimada A, Miyamoto K, Yoshida M, Yano S . Membranous nephropathy associated with psoriasis vulgaris. Clin Nephrol. 1994; 42(1):63-4. View

Kim M, Ko Y, Yeo U, Kim Y, Oh H . Psoriasis and glomerulonephritis. Clin Exp Dermatol. 1999; 23(6):295-6. DOI: 10.1046/j.1365-2230.1998.00373.x. View

Madeddu P, Ena P, Glorioso N, Cerimele D, Rappelli A . High prevalence of microproteinuria, an early index of renal impairment, in patients with diffuse psoriasis. Nephron. 1988; 48(3):222-5. DOI: 10.1159/000184916. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Dommasch E, Shin D, Troxel A, Margolis D, Gelfand J . Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol. 2009; 162(4):835-42. PMC: 2877159. DOI: 10.1111/j.1365-2133.2009.09589.x. View

Perazella M, Moeckel G . Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010; 30(6):570-81. DOI: 10.1016/j.semnephrol.2010.09.005. View

Booth N . What are the Read Codes?. Health Libr Rev. 1994; 11(3):177-82. DOI: 10.1046/j.1365-2532.1994.1130177.x. View

10.

Langan S, Seminara N, Shin D, Troxel A, Kimmel S, Mehta N . Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2011; 132(3 Pt 1):556-62. PMC: 3278499. DOI: 10.1038/jid.2011.365. View

11.

Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

12.

Smith C, Anstey A, Barker J, Burden A, Chalmers R, Chandler D . British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005; 153(3):486-97. DOI: 10.1111/j.1365-2133.2005.06893.x. View

13.

Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A . Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology. 1992; 185(2):93-5. DOI: 10.1159/000247420. View

14.

Dervisoglu E, Akturk A, Yildiz K, Kiran R, Yilmaz A . The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol. 2011; 44(2):509-14. DOI: 10.1007/s11255-011-9966-1. View

15.

Seminara N, Abuabara K, Shin D, Langan S, Kimmel S, Margolis D . Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol. 2010; 164(3):602-9. PMC: 3064479. DOI: 10.1111/j.1365-2133.2010.10134.x. View

16.

Yang Y, Keller J, Lin H . Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011; 165(5):1037-43. DOI: 10.1111/j.1365-2133.2011.10494.x. View

17.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

18.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

19.

Imai H, Kodama T, Ishino T, Yasuda T, Miura A, Asakura K . IgA nephropathy associated with hyper IgAnemia, psoriasis or pustulosis and ossification. Clin Nephrol. 1995; 44(1):64-8. View

20.

Yeung H, Takeshita J, Mehta N, Kimmel S, Ogdie A, Margolis D . Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013; 149(10):1173-9. PMC: 3800487. DOI: 10.1001/jamadermatol.2013.5015. View